China’s Nanjing King-Friend Takes Control Of US Injectables Specialist Meitheal

China’s Nanjing King-Friend Biochemical Pharmaceutical has taken a majority stake in US generic injectables specialist Meitheal Pharmaceuticals.

PieChart_Figures
Nanjing King-Friend Has Taken A Majority Share Of Meitheal • Source: Shutterstock

China’s Nanjing King-Friend Biochemical Pharmaceutical is paying $95m to increase its share in US generic injectables specialist Meitheal Pharmaceuticals to a majority stake, the two companies have announced.

Conducted through NKF’s wholly-owned subsidiary Hong Kong King-Friend Industrial Company, the deal is expected to close in the fourth quarter...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Deals

Nexus Faces Five Year Wait On Injectable Minocycline

Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.

Top 10 Drugs Q1 2026: New Sheriff In Town As Mounjaro Unseats Keytruda - Clone - Clone

Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains

test

uygukgigo

 
• By 

More from Business

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C9

 
• By 

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C8

 
• By 

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success

 
• By 

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.